Novartis announced results from an updated analysis of the pivotal Phase III NATALEE trial of Kisqali®? (ribociclib) that underscore the extended efficacy beyond the duration of treatment in combination with endocrine therapy (ET). Results showed a sustained reduction in distant recurrence of 28.5% The DDFS with Kisqali was consistent across all pre-specified patient subgroups, including those with node-negative (N0) disease1.

These late-breaking data are being presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).